.png)
Tempest, weathering stormy capital markets, hunts for partners for liver cancer drug
Unable to secure additional financing amid a stormy market, Tempest Therapeutics has put out a call for partners as it seeks to take its liver cancer drug into phase 3.
Unable to secure additional financing amid a stormy market, Tempest Therapeutics has put out a call for partners as it seeks to take its liver cancer drug into phase 3.
